ProShares Ultra Nasdaq Biotechnology (BIB)
NASDAQ: BIB · Real-Time Price · USD
111.11
+4.29 (4.02%)
At close: Oct 15, 2026, 4:00 PM EDT
111.19
+0.08 (0.07%)
After-hours: Oct 15, 2026, 7:30 PM EDT
| Assets | $91.39M |
| Expense Ratio | 0.95% |
| PE Ratio | n/a |
| Forward PE | n/a |
| Shares Out | 840,000 |
| Dividend | $0.22 (0.20%) |
| Ex-Dividend Date | Sep 23, 2026 |
| Payout Frequency | Quarterly |
| Payout Ratio | n/a |
| Volume | 8,444 |
| Open | 110.78 |
| Previous Close | 106.82 |
| Day's Range | 110.78 - 112.32 |
| 52-Week Low | 65.01 |
| 52-Week High | 126.40 |
| Beta | 1.20 |
| Holdings | 256 |
| Inception Date | Apr 8, 2010 |
About BIB
Fund Home PageThe ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index. The fund provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ. BIB was launched on Apr 8, 2010 and is issued by ProShares.
Asset Class Equity
Category Trading--Leveraged Equity
Stock Exchange Nasdaq
Ticker Symbol BIB
ETF Provider ProShares
Index Tracked NASDAQ / Biotechnology
Top 10 Holdings
156.07% of assets| Name | Symbol | Weight |
|---|---|---|
| NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA | n/a | 31.75% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA | n/a | 31.72% |
| NASDAQ BIO INDEX SWAP BNP PARIBAS | n/a | 29.05% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONAL | n/a | 20.19% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE | n/a | 19.23% |
| Gilead Sciences, Inc. | GILD | 5.48% |
| Amgen Inc. | AMGN | 5.18% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG | n/a | 4.81% |
| Vertex Pharmaceuticals Incorporated | VRTX | 4.79% |
| Moderna, Inc. | MRNA | 3.87% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 23, 2026 | $0.08255 | Sep 29, 2026 |
| Mar 25, 2026 | $0.00714 | Mar 31, 2026 |
| Dec 24, 2025 | $0.13464 | Dec 31, 2025 |
| Sep 24, 2025 | $0.18054 | Sep 30, 2025 |
| Jun 25, 2025 | $0.17058 | Jul 1, 2025 |
| Mar 26, 2025 | $0.13094 | Apr 1, 2025 |
Performance
BIB had a total return of 72.27% in the past year, including dividends. Since the fund's inception, the average annual return has been 18.04%.
News
Here is a List of Small-Cap Biotech ETFs to Watch for Big Gains in 2026
Biotech ETFs are regaining attention as analyst targets signal renewed upside heading into 2026, particularly among small- and mid-cap drug developers. The ProShares Ultra Nasdaq Biotechnology ETF ($B...
7 months ago - TipRanks